Bill > SJR115

This Joint Resolution establishes the New Jersey Pharmacogenomics Commission, a body tasked with studying pharmacogenomics, which is the science of how a person's unique genetic makeup influences how they respond to medications, including their effectiveness and potential side effects. The commission will investigate various aspects of pharmacogenomics, such as its costs, benefits to patients and healthcare providers, applications beyond medicine (like addressing the opioid crisis), its role in personalized medicine, and its potential to reduce adverse drug events, which are harmful reactions to medications. The commission will comprise eleven members appointed by the Governor from various healthcare and academic institutions, including representatives from the Department of Health, Rutgers Medical School, the New Jersey Hospital Association, and BioNJ, among others. After organizing and holding public hearings, the commission is required to submit a report with its findings and recommendations to the Governor and the Legislature within six months of its organization, after which it will be dissolved.